Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| International Agency for Research on Cancer | OTHER |
Not provided
Not provided
Not provided
Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-effects. Eligible patients must be between 3 years and 18 years of age at time of assent/consent, have newly diagnosed B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia confirmed by pathology report, and must be receiving treatment at one of the participating centers. Patients receiving hematopoietic cell transplant will be excluded. Institutions were selected to ensure representation of several global health indicators related to nutritional status and wealth classification according to the World Bank. Data related to demographic variables (socioeconomic status, food security), lifestyle habits (diet, physical activity), nutritional anthropometrics (height, weight and arm anthropometry), and nutritional biological indices (stool and blood) will be collected at designated timepoints throughout treatment and one year after the end of treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Create a prospective multinational biorepository of pediatric specimens (stool, blood) obtained at diagnosis, end of induction, beginning of maintenance, end of treatment, and 1-year after treatment among children/adolescents with ALL. | 7 years | |
| Collect sociodemographic data at sequential timepoints during treatment for ALL. | 7 years | |
| Collect dietary data at sequential timepoints during treatment for ALL. | 7 years | |
| Collect physical activity data at sequential timepoints during treatment for ALL. | 7 years | |
| Collect clinical information (disease characteristics, treatment-related toxicities, survival) at sequential timepoints during treatment for ALL to accompany the biorepository of blood and stool specimens. | 7 years | |
| Collect nutritional anthropometrics at sequential timepoints during treatment for ALL to accompany the biorepository of blood and stool specimens. | 7 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Patients receiving hematopoietic cell transplant.
Not provided
Not provided
Children and adolescents diagnosed with acute lymphoblastic leukemia
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elena Ladas, PhD, RD | Contact | +12123057835 | ejd14@cumc.columbia.edu | |
| Michelle Walters, MS, RD | Contact | +12128514995 | mw3328@cumc.columbia.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Columbia University Irving Medical Center | Active, not recruiting | New York | New York | 10032 | United States | |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| D065817 | Congenital Microtia |
| D020022 | Genetic Predisposition to Disease |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Stool and blood will be collected at diagnosis, end of induction, beginning of maintenance, end of treatment, and 1 year post end of treatment
| Hospital de Cancer Infanto Juvenil de Barretos |
| Recruiting |
| Barretos |
| Brazil |
|
| Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) | Recruiting | Recife | Brazil |
|
| Instituto de Tratamento do Câncer Infantil (ITACI) | Recruiting | São Paulo | Brazil |
|
| Unidad Nacional De Oncologia Pediatrica | Recruiting | Guatemala City | Guatemala |
|
| Hospital Escuela | Recruiting | Tegucigalpa | Honduras |
|
| Post-Graduate Institute of Medical Education and Research (PGIMER) | Recruiting | Chandigarh | India |
|
| Muhumbili Hospital | Recruiting | Dar es Salaam | Dar es Salaam Region | Tanzania |
|
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D004427 | Ear Diseases |
| D010038 | Otorhinolaryngologic Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D004198 | Disease Susceptibility |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |